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The 18th WHO Global Tuberculosis Annual Report indicates that there were an esti-
mated 8.6 million incident cases of tuberculosis (TB) in 2012, which included 2.9 million
women and 530,000 children. TB caused 1.3 million deaths including 320,000 human
immunodeficiency virus (HIV)-infected people; three-quarters of deaths occurred in Africa
and Southeast Asia. With one-third of the world’s population latently infected with
Mycobacterium tuberculosis (Mtb), active TB disease is primarily associated with a break
down in immune surveillance. This explains the strong link between active TB disease and
other communicable diseases (CDs) or noncommunicable diseases (NCDs) that exert a toll
on the immune system. Comorbid NCD risk factors include diabetes, smoking, malnutrition,
and chronic lung disease, all of which have increased relentlessly over the past decade in
developing countries. The huge overlap between killer infections such as TB, HIV, malaria,
and severe viral infections with NCDs, results in a “double burden of disease” in developing
countries. The current focus on vertical disease programs fails to recognize comorbidities or
to encourage joint management approaches. This review highlights major disease overlaps
and discusses the rationale for better integration of tuberculosis care with services for NCDs
and other infectious diseases to enhance the overall efficiency of the public health responses.
During the past two decades, health prior-ities in developing countries have been
determined primarily by the epidemics of kill-
er infectious diseases, particularly tuberculosis
(TB), HIV/AIDS (acquired immunodeficiency
syndrome), and malaria. The 2013WHOGlobal
TB report estimates that 8.6 million TB cases
occurred in 2012, causing 1.3 million deaths of
which 320,000 were in HIV-infected people
(WHO 2013). Three-quarters of TB deaths oc-
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curred in Africa and Southeast Asia, with South
Africa and India accounting for one-third of
all deaths. An estimated 3 million people with
active TB were either not diagnosed or diag-
nosed but not reported. Copresentation of se-
verely ill patients with other communicable and
noncommunicable diseases (NCDs) is a major
cause of TB-associated deaths (Bates et al. 2012;
Geneau and Hallen 2012; Remais et al. 2013)
(Table 1).
The global burden of NCDs, particularly
cancer, cardiovascular disease, diabetes, and
chronic respiratory disease, accounts for nearly
half of all disability and two-thirds of deaths
worldwide (Beaglehole et al. 2011; WHO
2011). The prevalence of NCDs is increasing
the fastest in low- andmiddle-income countries
and impacting disproportionately on disadvan-
taged communities. In 2010, more than 2 mil-
lion deaths attributable to NCDs occurred in
sub-Saharan Africa, a 46% (95% CI 41–59) in-
crease from 1990 (Lozano et al. 2012). In de-
veloping countries, major demographic shifts,
urbanization, changing environmental factors,
economic empowerment, and accompanying
lifestyle changes have led to a rapid increase
in NCDs (Lim et al. 2012). Undernutrition, to-
bacco use, the growing diabetes epidemic,
and indoor air pollution are also impacting
TB control adversely in Southeast Asian na-
tions. In the sub-Saharan African context, the
impact of the HIVepidemic is more significant
on TB. So prevention and treatment policy and
programming have to take these factors into
account.
The convergence of certain NCDs with TB
and other communicable diseases now poses
concurrent health challenges, which requires a
radical shift in emphasis toward multidisci-
plinary collaboration and integrated strategies.
Health services in resource-limited countries
are not tailored to deal with this double burden
of disease, and thus simple and effective adjust-
ments to health systems are required, which can
significantly improve joint care (Adeyi and Ro-
bles 2007). In high comorbidity populations, it
is critical that healthministries, and nongovern-
mental intervention and research organizations,
appreciate the limitations of vertical approaches
focused on individual diseases.
Table 2 illustrates synergies between TB and
NCDs that could be explored in public health
efforts, such as joint health promotion strate-
gies, reciprocal screening programs, and coor-
dinated treatment. Figure 1 provides absolute
and attributable TB risk estimates for diabetes,
malnutrition, smoking, excessive alcohol use,
and HIV infection. A review of autopsies per-
formed on patients who died with TB in Lon-
don determined that 35 out of 46 cases had
comorbidities, which were primarily hepatitis
C virus and HIV infections, cancer, cardiovas-
Table 1. Key messages
TB comorbidity with noncommunicable diseases
(NCDs) and other communicable diseases (CDs)
is highly prevalent in TB endemic regions of the
world. Population attributable TB risk estimates
for diabetes, malnutrition, smoking, excessive
alcohol use, and HIV infection are high.
Traditional vertical (disease-specific) approaches to
health care services delivery often fail to recognize
potential synergies. Wider integration of TB
control activities present opportunities to explore
commonalities and optimize synergies without
sacrificing recent gains or eroding the
functionality of existing programs.
The lethal bidirectional interaction between TB and
HIV coinfection in sub-SaharanAfrica exemplifies
the need for well-integrated approaches to disease
management and control.
The looming threat of diabetesmellitus (DM) andTB
also calls for bidirectional screening and the need
to tackle a broader range of overlapping diseases in
resource-poor countries. High levels of TB
comorbidity in patients admitted to hospital with
CDs or NCDs and in pregnant women attending
antenatal clinics are easily overlooked in TB
endemic areas.
Efficient integration of TB services should be
encouraged, while maintaining some vertical
elements to secure essential functions such as drug
supply, monitoring and evaluation, and national
surveillance, to a point in which the national TB
program may be limited to a small central team
providing general oversight.
M. Bates et al.
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cular disease, and chronic obstructive pulmo-
nary disease (COPD) (Sbrana et al. 2011). This
review describes the major comorbidities asso-
ciated with active TB disease, describes key clin-
ical and molecular interactions, and discusses
the implications for disease control policy.
TUBERCULOSIS AND
NONCOMMUNICABLE DISEASES
Diabetes
The epidemiological link between diabetes and
TB is well established, but during the last half
century, populations that have developed high
rates of diabetes (wealthier, overnourished,
more sedentary working environments) have
been distinct from those still dogged by ram-
pant TB (poorer, undernourished, persistence
of grueling manual working environments).
Increasing industrialization and urbanization
in developing countries are leading to growth
in rates of diabetes, leading to a potentially
cataclysmic confluence of NCDs (of which di-
abetes is one of the most common) and CDs
(of which TB is the most common). In parts of
India and China, this has already become a
reality, as swathes of the traditionally rural pop-
ulous flock to overcrowded dwellings in urban
centers to take up minimum wage employment
in poorly ventilated factories and mines (Li
et al. 2012; Lin et al. 2012; Viswanathan et al.
2012).
Several large case-controlled and longitudi-
nal cohort studies have shown that the relative
odds of developing active TB ranges from two
to eight in diabetic patients versus nondiabetic
controls (reviewed by Dooley and Chaisson
2009). These studies were in different popula-
tions globally, controlling for the particular risk
factors, which predominate in each study pop-
ulation. A recent meta-analysis concluded that
diabetes patients were 3.1 more likely to de-
velop active TB than controls, although relative
risk was lower in North American study popu-
lations (Jeon andMurray 2008). TB is alsomore
likely in insulin-dependent versus non-insulin-
dependent diabetes patients (Olmos et al. 1989;
Swai et al. 1990; Leung et al. 2008).
Studies have shown a negative impact of
diabetes on treatment outcomes including an
up to fourfold increase in the risk of treatment
failure (Mboussa et al. 2003; Morsy et al. 2003;
Alisjahbana et al. 2007). Studies from Turkey
and the United States following up patients
for a shorter period suggest that diabetes is
linked with modest delays in clearance (Guler
et al. 2007; Restrepo et al. 2008), although one
Indian study found that whereas diabetes pa-
tients were more likely to be smear-positive
(which bodes well for diagnosis), they had high-
er smear conversion rates at 3 mo (Singla et al.
2006).
Table 2. Differences, similarities, and potential syn-
ergies between tuberculosis (TB) and noncommuni-
cable diseases (NCDs)
Differences and similarities
Tuberculosis NCDs
Transmissible Not transmissible
Infection control
important
No infection control
issues
Need to prevent Need to prevent
POC testing problematic POC testing common
Curable Rarely curable
Long-term treatment Long-term
management
Major adherence issues Major adherence issues
Require lifestyle changes Require lifestyle
changes
Most cases can bemanaged
at primary HC level
Most cases managed at
primary HC level
Potential synergies
Reciprocal screening for TB, other CDs (malaria,
HIV) and NCDs
Combined health messaging and communication
strategies
Coordinated human resource development/training
opportunities
Combined infrastructure development
Cross-utilization of health care workers
Unified point of care; avoids multiple clinic
attendances
Integrated recording/reporting systems
Opportunities for community and user education/
engagement
Poverty alleviation strategies
Creating an environment that sustains health and
well-being
POC, point of care.
TB and Comorbidities with CDs and NCDs
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There are reports for and against an associ-
ation between diabetes and drug-resistant tu-
berculosis (Dooley and Chaisson 2009), with
possible explanations including delayed clear-
ance resulting in routine switching to a two-
drug regimen in patients who are still culture-
positive or lowered rifampicin levels in diabetes
patients (Nijland et al. 2006). Among TB pa-
tients, having diabetes is linked with a signifi-
cant increase in the risk of death (Dooley et al.
2009; Ismail and Bulgiba 2013). Very little of the
available data comes from sub-Saharan African
populations, where diabetes prevalence will in-
crease over the next decade (Dooley and Chais-
son 2009) and where TB and diabetes treatment
decisions for significant numbers of patients
will have to frequently accommodate antiretro-
viral therapy, which itself is associated with in-
creased risk of TB (Marais et al. 2013). Diabetes
mellitus (DM) increases the risk of active TB
by a factor of 2 to 3. In addition, people with
TB, who have diabetes, have been found to have
worse TB treatment outcomes. The WHO and
The International Union Against Tuberculosis
and Lung Disease Framework for Collabora-
tive Activities recommend screening for TB
and diabetes simultaneously. The recommend-
ed collaborative activities, outcome indicators,
and research areas for guiding public health pol-
icies for joint TB and diabetes care recommend
screening for active TB in patients with diabetes
and for diabetes in patients with TB to make
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Figure 1. Estimates of population attributable to TB disease risk caused by HIV, undernutrition, smoking,
diabetes, and alcohol abuse. AFR high HIV: African countries with high HIV prevalence. AFR low HIV: African
countries with low/moderate HIV prevalence. CEUR: Central European countries. EEUR: Eastern European
countries. EME: Established market economies. EMR: Eastern Mediterranean region. LAC: Latin American
countries. SEAR: Southeast Asian region. WPR: Western Pacific region (except EME). Population attributable
fraction (PAF) ¼ [prevalence  (relative risk 2 1)]/[prevalence  (relative risk 2 1) þ 1]. Point estimates
of relative risk from systematic reviews were used. When prevalence was only available for adults, the prevalence
in adults was adjusted for proportion of population under the age of 15 to estimate the total population PAF.
HIV (human immunodeficiency virus infection): Relative risk ¼ 27. Undernourishment (undernutrition): Rela-
tive risk ¼ 3.2 (for BMI 16 vs. BMI 25). Diabetes (DM, diabetes mellitus): Relative risk ¼ 3.1. Alcohol abuse:
Relative risk ¼ 2.9. Prevalence data: Average of prevalence of heavy drinking in China, Brazil, India, Nigeria,
Pakistan, Russia, South Africa, and Thailand. Smoking (cigarette smoking): Relative risk ¼ 2.0 (current vs. never
smokers). (Adapted from Lo¨nnroth et al. 2010 and Creswell et al. 2011.)
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earlier diagnoses, which in turn may lead to
better treatment outcomes and control of both
diseases (Table 3) (WHO/IUATBLD 2011]).
Malnutrition
Malnutrition is a risk factor for all infectious
diseases because it impairs immunity. Both
protein calorie malnutrition (PCM) and mi-
cronutrient deficiencies can cause immune sup-
pression through a variety of mechanisms, as
reviewed in Bhaskaram (2002) and Schaible
and Kaufmann (2007). Chronic malnutrition
has a great impact on chronic infectious diseases
such as HIVand TB, which require constant im-
mune surveillance and control. The prevalence
of malnutrition, generally defined by a BMI of
,18.5 kg/m2, among adult pulmonary TB
patients can range from 42% to 80% (Kennedy
et al. 1996; Zachariah et al. 2002; Dodor 2008;
Mupere et al. 2012; Bhargava et al. 2013). In the
African studies, the prevalence of malnutrition
was lower among women, whereas in the Indian
study, itwas loweramongmen.These studies did
not compare the prevalence of malnutrition
among TB patients with that of the general pop-
ulation, but they did look at the effect of mal-
nutrition on TB treatment outcomes. Three
of these studies showed improvements in nutri-
tional status with TB treatment, but weight gain
did not correlate with microbiological response
and significant numbers of patients cured of
TB were still underweight at 12 mo, indicating
the overriding influence of socioeconomic fac-
tors (Kennedyet al. 1996;Dodor 2008; Bhargava
et al. 2013). A Korean study also found malnu-
trition to be associated with poorer outcomes in
disseminated TB (Kim et al. 2008). One Tanza-
nian study identified TB as an important corre-
late of wasting, independent of HIV (Villamor
et al. 2006), and Malawian, Ugandan, and Indi-
an studies found that severe malnutrition on
admission was independently linked with in-
creased risk of early mortality (Zachariah et al.
2002; Mupere et al. 2012; Bhargava et al. 2013).
A Latvian study found that being underweight
was linked with worse outcomes and increased
mortality in multidrug-resistant (MDR)-TB
(Podewils et al. 2011).
Children primarily acquire active TB from
adults with whom they live, and so one would
expect the prevalence of malnutrition among
children with TB to be similar if not higher
than among adult TB patients, with households
affected by malnutrition more likely to suffer
transmission events from infected adults to
children. A study from Pakistan found 51% of
children initiating TB therapy to have PCM
(Uddin Siddiqui et al. 2010), and there is a
need for more research to evaluate possible in-
terventions to cotreat malnutrition and tuber-
culosis and to assess to what degree nutritional
interventions might be able to prevent the de-
velopment of active TB in high-risk children
(Jaganath and Mupere 2012).
TUBERCULOSIS AND OTHER
COMMUNICABLE DISEASES
HIV/AIDS
In the early 1990s, researchers started to ask
questions about the effect of HIV coinfection
on TB prevalence, drug reactions, and treat-
ment outcomes. A U.S. study of prisoners was
the first paper in which the term “coinfection”
was used with respect to HIV and TB (Salive
et al. 1990). Subsequent studies in various pa-
tient groups showed significantly higher preva-
lence ofHIV-1 infection inTBpatients (Singh et
al. 1993; Greenberg et al. 1994; Kivihya-Ndugga
et al. 1994a), including children (Chintu et al.
1993), showing associations with more severe
disease (Kivihya-Ndugga et al. 1994a), more ad-
vanced immune suppression (Kivihya-Ndugga
et al. 1994b; Martin et al. 1995), and drug reac-
tions (Pozniak et al. 1992).
In the subsequent two decades, the HIVep-
idemic has expanded dramatically in some
countries, dragging both pulmonary and ex-
trapulmonary TB in its wake, fueling a fivefold
increase in TB notification rates between 1990
and 2010 in sub-Saharan Africa, which bears
80% of the global HIV disease burden. HIV
increases TB risk by 20- to 40-fold and TB ac-
counts for 25% of HIV-related deaths world-
wide—the single largest cause. TheWHOGlob-
al Tuberculosis Report 2013 states that 13%
TB and Comorbidities with CDs and NCDs
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Table 3. Recommended collaborative activities, outcome indicators, and research areas for guiding public
health policies for joint TB and diabetes care
Area Recommendation
A. Establish mechanisms for collaboration
A.1. Setupmeans of coordinating diabetes and TB
activities
A.2. Conduct surveillance of TB disease
prevalence among people with diabetes in
medium and high TB burden settings
A.3. Conduct surveillance of diabetes prevalence
in TB patients in all countries
A.4. Conduct monitoring and evaluation of
collaborative diabetes and TB activities
Recommendation 1: Joint coordination should be
established at regional, district, and/or local levels
(sensitive to country-specific factors), with
representation from all relevant stakeholders. A joint
plan for diabetes and TB activities should be drawn up
and reflected in national plans on noncommunicable
diseases and TB, respectively.
Recommendation 2: There should be TB surveillance
among diabetes patients in settings with medium to
high TB burden.
Recommendation 3: There should be surveillance of
diabetes among TB patients in all countries.
Recommendation 4:Where diabetes and TB collaboration
is being established, programs for both diseases should
agree on a core set of indicators and data collection
tools for the monitoring and evaluation of
collaborative activities. Diabetes programs should
explore the possibilityof adapting the directlyobserved
therapy (DOT) system tomonitor and report cases and
treatment outcomes.
B. Detect and manage TB in patients with diabetes
B.1. Intensify detection of TB among people with
diabetes
B.2. Ensure TB infection control in health-care
settings where diabetes is managed
B.3. Ensure high-quality TB treatment and
management in people with diabetes
Recommendation 5: At a minimum, people with diabetes
should be asked about the presence of cough (lasting
.2 wk) at the time of diabetes diagnosis, and if
possible at each regular check-up for diabetes. Those
with positive symptoms should be examined as per
national guidelines. Other diagnostic procedures, such
as those for extrapulmonary TB, should be pursued
rigorously as per national guidelines.
Recommendation 6: Screening for active TB on broader
indications (e.g., in all people diagnosed with diabetes,
regardless of symptoms) should be explored as part of
the research agenda for improved TB diagnosis among
people with diabetes.
Recommendation 7: A referral system should be
established so that patients with suspected TB are
promptly sent to TB diagnostic and treatment centers
and evaluated in accordance with the guidelines of the
national TB control program.
Recommendation 8: Tuberculosis case finding should be
intensified by increasing the awareness and knowledge
of the interactions between diabetes and TB, including
joint risk factors, among health-care workers and
populations they serve.
Recommendation 9: Each health-care facility, including
diabetes clinics, should have an infection control plan
(including a plan for TB infection control), which
includes administrative and environmental control
Continued
M. Bates et al.
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(1.1 million) of 8.6 million people who devel-
oped TB in 2012 are coinfected with HIV
(WHO 2013). With respect to HIV/TB, the re-
port highlights some modest improvements—
coverage of ART (antiviral therapy) and cotri-
moxazole preventative therapy have improved
amongHIV-positive TB patients in recent years.
Isoniazid preventive therapy (IPT) was provid-
ed to one-third of all new HIV cases diagnosed
in 2012, although 50% are likely eligible. It re-
mains unclear how appropriate this is in ex-
tremely high-burden settings.
As one of five key priority areas, the report
highlights the need for improved coverage of
dual HIV/TB testing, which in some countries
approaches 100%, indicating what is possible.
LowHIVburden countries have hadmore prob-
lems, or shown less initiative, in promotingHIV
counseling and testing among newly diagnosed
TB patients. In the Africa region, the epicenter
of the HIV pandemic, up to 77% of TB patients
are coinfected with HIV, and the rate of TB pa-
tients who have undergone HIV testing has in-
creased dramatically in recent years. Seven high-
burden countries, mainly from Eastern and
Southern Africa, have HIV testing rates in TB
clinics higher than 90%, lead by Zambia, the
only country to test virtually all notified TB
Table 3. Continued
Area Recommendation
measures to reduce transmission of TB within this
setting. These measures should adhere to WHO’s
International guidelines for TB infection control.
Recommendation 10: Treatment and case management of
TB in people with diabetes should be provided in
accordance with existing TB treatment guidelines and
international standards. The same TB treatment
regimen should be prescribed to people with diabetes
as for people without diabetes.
C. Detect and manage diabetes in patients with TB
C.1. Screen TB patients for diabetes
C.2. Ensure high-quality diabetes management
among TB patients
Recommendation 11: TB patients should be screened for
diabetes at the start of treatment. Type of screening and
diagnostic tests should be adapted to the context of
local health systems and the availability of resources,
while awaiting additional evidence on the best
screening and diagnostic approach.
Recommendation 12: Management of diabetes in TB
patients should be provided in line with existing
guidelines.
D. Key processes, outcome indicators, and research
questions
1. Joint TB and diabetes plan in place
2. Number and proportion of people with diagnosed
diabetes who have been screened for chronic cough
3. Number and proportion of people with diabetes
who have been tested for TB (radiography, sputum
smear microscopy, culture, Xpert MTB/Rif Assay,
etc.)
4. Prevalence of TB among people with diabetes
5. Number and proportion of peoplewith TBwho have
been screened for diabetes
6. Prevalence of diabetes among people with TB
7. TB treatment outcomes among people with diabetes
Data adapted from WHO/IUATBLD 2011.
TB and Comorbidities with CDs and NCDs
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cases for HIV. Because HIV status may inform
on treatment decisions in comorbid patients
(e.g., toxicities and pharmacokinetic interac-
tions of TB and ARTor other drugs), Diagnostic
Counseling and Testing (DCT) or “opt out”
strategies have been instigated in some in-pa-
tient settings and high-risk groups. In recent
years, WHO has invested in improved data col-
lection systems for TB/HIV; however, in many
countries, there is still a great need for improved
data collection, with data frombothHIVandTB
programs irreconcilable in some cases. There are
also still significant patient groups that go under
the radar and are not captured. For example,
data from Zambia shows that TB is frequently
missed in a range of hospitalized patients, at-
tributable to overriding symptoms indicative
of one or more comorbid communicable or
noncommunicable diseases (Bates et al. 2012).
Those who are discharged should be referred
back to their community TB treatment center,
but there are no funds to follow up such cases,
and the large numberofmissedTBpatients who
die shortly after admission are not reported to
the National Tuberculosis Programmes (NTPs).
Most importantly, rates of MDR-TB within this
high morbidity and mortality, HIV-positive in-
patient group may approach 10%, resulting in
possible gross underestimation ofMDR-TB cas-
es in what are currently considered to be rela-
tively low MDR-TB prevalence countries (Bates
et al. 2012).
The treatment of HIVand TB in coinfected
patients is potentially complicated by toxicities
and pharmacokinetic interactions between the
drugs used in anti-TB and ART, but because
of the considerable number of drugs available,
regimens can often be adjusted to reduce side
effects and nonadherence (Arentz et al. 2012).
HIV-infected TB patients initiated on ART
benefit from increased survival and cure rates,
whether on first-line (Gengiah et al. 2011) or
second-line anti-TB therapy (Arentz et al.
2012). WHO recommend that ART should be
commenced as soon as possible after initiating
TB treatment, especially in patients with CD4
counts of ,50 cells/mL, but early mortality re-
mains a significant problem in patients initiat-
ing ARTand trials are under way to evaluate the
possible benefits of presumptive TB treatment
in high-risk patients with very low CD4 counts
(Zumla et al. 2013).
In sub-Saharan Africa, TB now supersedes
obstetric causes of death in HIV-infected preg-
nant women, with vertical transmission of TB
occurring in up to 15% of neonates born to
mothers suffering from HIV/TB coinfection
(Adhikari et al. 2011; Bekker et al. 2012). With
HIV-infected persons living longer on ART
(Volberding and Deeks 2010; Ullrich et al.
2011), and the huge success of interventions to
reduce mother-to-child-transmission (MTCT)
of HIV (Sturt et al. 2010), the number of chil-
dren born to HIV/TB coinfected mothers is set
to increase and so is the burden of neonatal TB.
There is a need for more research into possible
ways to preventMTCTof TB and on how best to
diagnose and treat TB in the HIV-exposed neo-
nate,which compounds just about all diagnostic
and treatment challenges seen in other patient
groups.
Malaria
Although there is considerable literature on
HIV/tuberculosis and HIV/malaria coinfec-
tions and comorbidity, there has been dis-
tinctly less attention given to both clinical
and immunological interactions between TB
and malaria. Unlike HIV, both Mycobacterium
tuberculosis (Mtb) and Plasmodium species are
ancient pathogens that have coevolved in the
same human populations over millennia, with
molecular evidence for coinfections shown in
2000–3000-yr-old mummified remains from
lower Egypt (Lalremruata et al. 2013). When
two chronic pathogens have coevolved in the
same population, it is possible (if not highly
likely) that they have evolved mutually bene-
ficial “win–win” strategies, to aid their own
persistence and transmission. Could there be
molecular synergies between plasmodium and
Mtb that contribute to each other’s persis-
tence in endemic regions (Enwere et al.
1999)?
Animalmodel studies suggest infectionwith
malaria induces immune responses that impair
host resistance to chronic TB infection, with
M. Bates et al.
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exacerbated leukocyte infiltrates, tissue pathol-
ogy, and hypercytokinemia accompanied by
altered T-cell responses, pointing tomalaria-in-
duced dysregulation of innate and adap-
tive antimycobacterial defenses (Hawkes et al.
2010; Mueller et al. 2012). Other animal model
studies have shown that coinfected mice were
less able to inhibitMtb growth in lungs, spleen,
and liver (Scott et al. 2004) and that TB and
malaria trigger similar innate immune respons-
es such as the heme oxygenase 1 pathway, en-
hancing the efficiency of the liver stage in the
Plasmodium life cycle (Sinnis and Ernst 2008).
Conversely, it is also possible that under cer-
tain circumstances, coinfecting pathogens may
possess competitive strategies, with one study
showingMtb-induced protective effects against
lethal murine malaria (Page et al. 2005). Anoth-
er study showed that murine malaria infection
did not have any effect on vaccine-induced TB
immunity (Parra et al. 2011).
There are few studies that document cross-
sectional prevalence of malaria in TB patients,
with rates ranging from 5% to 37%, because of
differences in study location, population, and
definitions used (Range et al. 2007; Valadas et
al. 2013). Malaria infection can inhibit TB in-
terferon-g release assays (IGRAS) (Banfield et
al. 2012), but this is mute, in that these diagnos-
tics are not generally recommended for use in
high-burden populations. There are also some
potential drug interactions that should be con-
sidered when treating coinfected patients. Fluo-
roquinalones are contraindicated with other
drugs that prolong ventricular repolarization,
recorded as lengthening of the QT interval on
an electrocardiogram (Murphy et al. 2012). In-
duction of the hepatic cytochrome P450 en-
zyme system by rifampicin results in a halving
in the serum concentrations of artemisinin
and its derivatives, complicating the concurrent
management of TB and acute malaria. There is
a case report in the literature of malaria and TB
coinfection presenting as sepsis in a neonate
(Thapa et al. 2010). This is of potential impact
in that blood cultures from neonates with sus-
pected sepsis are often negative, with testing for
nonbacterial infections such as malaria and TB
often overlooked.
Influenza
Data from the 1918 influenza epidemic sug-
gested a clear association with increased risk
for TB-related disease and death during this
time period. Mouse models have shown that
prior exposure to influenza A impairs immune
responses to Mtb infection and decreases sur-
vival (Redford et al. 2014), possibly through
down-regulated MHC (major histocompatibil-
ity complex) expression on dendritic cells and
reduced activation of CD4 and CD8 T cells to
clear mycobacteria (Florido et al. 2013). A sim-
ilar murine study found influenza had little
effect on mycobacterial load (Co et al. 2006).
Clinical data from Southeast Asia does not sup-
port an association between influenza and TB
(de Paus et al. 2013; Noh et al. 2013; Roth et al.
2013). Even studies from high HIV burden pa-
tient groups in South Africa have found TB
coinfection in the 2009 H1N1 outbreak to be
rare in influenza deaths (10%), with pregnancy
being a more potent risk factor (Archer et al.
2009).
Other acute respiratory tract infections are
also likely to increase patients’ vulnerability to
developMtb infection or disease, and may par-
tially explain some of the seasonal variability
observed in temperate regions. A randomized
controlled trial to assess the impact of pneumo-
coccal vaccination showed decreased rates of
culture-confirmed and clinically diagnosed TB
in vaccinated children (Moore et al. 2010). Case
ascertainment bias could not be excluded, be-
cause unvaccinated children had more frequent
respiratory illness warranting diagnostic work-
up, but it offers the intriguing possibility that
pneumococcal coinfection may increase child-
ren’s vulnerability to develop active TB.
Helminths
There is increasing recognition that a high ex-
posure to pathogens in poorcommunities living
in tropical and subtropical regions results in
immunological profiles with different responses
to TB infection (Black et al. 2002). AU.S. study
of refugees from TB-endemic countries (free of
any acute illness or recent treatment history)
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showed that among those latently infected with
TB, those with concurrent helminth or Heli-
cobacter pylori infections had raised levels of
IFN-g and other cytokines. H. pylori was as-
sociated with enhanced IFN-g responses to
TB (Perry et al. 2013). A recent review conclud-
ed that there is now strong evidence that hel-
minth-inducedT-cell responses impair defenses
against Mtb infection, with consequences not
only for disease prevalence and severity in dif-
ferent regions, but also with respect to TB vac-
cine efficacy (Rafi et al. 2012). However, there is
murine data showing TB vaccine responses are
unaffected by helminth-induced Th2 responses
(Frantz et al. 2010) and that helminth infection
does not exacerbate TB disease (Hubner et al.
2012). Another rodent model showed that prior
helminth infections appear to illicit a macro-
phage response, which is protective during the
early stages of mycobacterial infection (du Ples-
sis et al. 2013).
Human studies in high- and low-burden
helminth infection populations found no dif-
ferences in tuberculin skin test responses in pa-
tients with and without helminth infections,
or after treatment with albendazole (Pelly et al.
2005; Zevallos et al. 2010). Looking in more
detail at components of the immune response,
there is evidence for helminth-associated reg-
ulatory T cells suppressing responses to BCG
(Bacillus Calmette-Gue´rin) vaccination in chil-
dren (Wammes et al. 2010) and Mtb-specific
Toll-like receptor expression in adults (Babu
et al. 2009). Ex vivo studies in whichmonocytes
differentiated into dendritic cells and macro-
phages, and then stimulated in vitro with live
Table 4. Social determinants and clinically observed associations with the development of tuberculosis
Social determinants
Living conditions
Poverty
Crowded accommodation with poor
ventilation (e.g., prisons, refugee camps,
homeless shelters, mass gatherings, shanty
towns)
Under/malnutrition (including
micronutrient deficiencies)
Poor health services
Alcohol or substance misuse
Cigarette smoking (active or passive)
Indoor biomass fuel smoke exposure
Birth or residence in TB endemic country
Visit to or regular close contact with people
from TB endemic countries
High-risk work or living environment
Mine workers
Health care workers
Laboratory personnel
Residential care staff
Inpatients in hospitals
Prisoners and prison staff
Refugee camp workers
Homeless
Migrants and nomads
Clinically observed associations
Other communicable diseases
HIV/AIDS
Sexually transmitted infections
Infections linked to injection drug use
Acute lung infections (viral, bacterial, fungal)
Chronic helminth infestations
Noncommunicable diseases
Diabetes mellitus
Chronic lung disease (e.g., COPD, pneumoconiosis)
Chronic kidney disease or end stage renal failure
Gut malabsorption or gastric bypass surgery
Skin disorders (e.g., psoriasis, alopecia areata)
Sarcoidosis
Congenital and other immunodeficiencies
Autoimmune diseases
Solid organ transplants
Cancers
Immunosuppressive therapy
Steroids (e.g., prednisone, methylprednisolone)
Antimetabolites (e.g., methotrexate, azathioprine)
T-cell inhibitors (e.g., cyclosporin, tacrolimus)
Alkylating agents (e.g., cyclophosphamide)
Biologicals (e.g., anti-TNF-a drugs, IL-2 blockers)
Pregnancy and childbirth
Extremes of age
Elderly
Very young
M. Bates et al.
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Table 5. Priorities for integration of tuberculosis care with that of other communicable and noncommunicable
diseases (CDs and NCDs)
TB and HIV services
Joint services
Family clinics for family diseases
Optimized infection control
Pragmatic screening and active case-finding strategies
HIV patients regularly screened for TB and all TB patients routinely tested for HIV infection, especially where
HIV prevalence exceeds 1%
Screening package to include weight and growth monitoring, blood pressure, blood sugar/HbA1c,
and cholesterol if indicated
TB and diabetes programs
Pragmatic screening and active case-finding strategies
All diabetes patients regularly screened for TB, and TB patients routinely tested for diabetes (random glucose
of HbA1c), especially in highly prevalent areas
Enhanced disease control
Shared treatment supervision (e.g., DOT for diabetes and TB)
TB, smoking cessation, and chronic respiratory care
Linking smokers diagnosed with TB to smoking cessation programs
Linking TB patients with chronic lung disease to ongoing respiratory care
Supporting and enhancing existing PAL projects
Regular TB screening in smokers/people with COPD (especially in TB endemic areas)
TB and alcohol/substance abuse care programs
Screening for harmful drinking and alcohol use disorder in TB patients
Linking TB patients with abuse problems to outreach and other care programs
Increasing TB risk awareness and symptom-identification in substance abuse program
Maternal and child health initiatives and services
Antenatal and obstetric services
Routine screening for HIV, TB, malaria (in endemic areas), DM, and hypertension
Routine STD screening
Administration of BCG vaccination to newborns
Child health
Routine administration of expanded EPI with hepatitus B, Haemophilus influenza type B, pneumococcal,
rotavirus, and HPV vaccines
Regular monitoring and mapping of weight gain on a “Road to Health chart”
Inclusion of pediatric TB in integrated management of childhood illness (IMCI) approaches
Regular deworming
Public health and advocacy campaigns
Reduce poverty and deprivation
Promote healthy living
Reduce cigarette smoking (tobacco control), solid fuel use
Reduce excessive alcohol use/substance abuse
Improve health literacy
Modified and adapted from Marais et al. 2013, with permission.
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microfilariae, resulted in cytokine and chemo-
kine expression that would impair the immune
response (Talaat et al. 2006). But do these cell
responses translate to poorer clinical outcomes?
One large well-controlled trial found that treat-
ment of helminths did not affect vaccine re-
sponses inUgandan children (Webb et al. 2011).
NEED FOR INTEGRATED STRATEGIES
With diminishing investment in global health,
integrated solutions should seek to unlock la-
tent synergies and optimize resource utilization.
It is particularly important to encourage local
ownership and increase equitable domestic
investment in health and sustainable develop-
ment. Rates of TB provide a useful barometer as
an “indicator disease” of socioeconomic in-
equality and deprivation (see Table 4). However,
meeting the social and medical care needs of
vulnerable communities requires a cohesive re-
sponse from multiple role players. Within the
emerging post-2015 development framework, it
is essential to emphasize the strong link between
health and responsible development, with TB
providing a classic example of two-way causal-
ity. Governments need to develop national
health strategic plans that integrate surveillance,
diagnostic, and treatment systems to meet the
challenges posed by current CD and NCD epi-
demics including new epidemics and drug-re-
sistant infections. Priorities for integration and
alignment of TB care with that of other com-
municable and noncommunicable diseases
(CDs and NCDs) are listed in Table 5. Wider
integration of TB control activities presents op-
portunities to explore latent synergies and get-
ting convergence for achieving universal health
care within programs.
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